1
Kenneth R Sidman: Biodegradable, implantable drug delivery depots, and method for preparing and using the same. Arthur D Little, Richard J Hammond, May 22, 1984: US04450150 (297 worldwide citation)

An implantable drug deliver depot comprising a hydrophilic poly(glutamic acid-co-ethyl glutamate) structure having one or more substances, e.g., drugs and/or diagnostic agents physically contained therein. The drug or diagnostic agent is released by its permeation of and diffusion through the copoly ...


2
Ernst B Hunziker: Methods and compositions for the treatment and repair of defects or lesions in cartilage or bone. Robert Francis Shaw, Edward F Mullowney, Jane A Massaro, December 14, 1993: US05270300 (279 worldwide citation)

Methods and compositions are provided for the treatment and repair of defects in the cartilage or bone of humans and other animals as in full-thickness defects in joints. The defect in bone is filled with a matrix having pores large enough to allow cells to populate the matrix and to form blood vess ...


3
Joel Habener: Insulinotropic hormone. The General Hospital Corporation, Sterne Kessler Goldstein and Fox, June 9, 1992: US05120712 (136 worldwide citation)

A fragment of glucagon-like peptide I (GLP-1) has been found to be an insulinotropic hormone. This insulinotropic hormone comprises amino acid residues 7-37 of GLP-1. The insulinotropic hormone is useful as a potential therapy for Diabetes Mellitus.


4

5
Arthur J Ammann, Christopher G Rudman: Method of inducing bone growth using TGF-.beta.. Genentech, Janet E Hasak, October 27, 1992: US05158934 (108 worldwide citation)

A method is provided for generation of bone at a site of an animal where skeletal tissue is deficient comprising administering to the animal, locally at the bone site in the presence of a source of osteogenic cells, an effective amount of a composition comprising TGF-.beta. in a pharmaceutically acc ...


6

7
Yoshiya Yamahira, Keiji Fujioka, Shiegeji Sato, Yoshihiro Takada: Long-term sustained-release preparation. Sumitomo Pharmaceuticals Company, Birch Stewart Kolasch & Birch, September 27, 1988: US04774091 (96 worldwide citation)

A solid sustained-release preparation in the form of a needle-like or bar-like shape, which consists essentially of an active ingredient and a pharmaceutically acceptable biodegradable carrier (e.g. proteins, preferably collagen, gelatin, and a mixture thereof). The sustained-release preparation can ...


8
Colin G Pitt, Robert M Platz: Pulmonary administration of erythropoietin. Amgen, Daniel M Chambers, Ron K Levy, Steven M Odre, October 11, 1994: US05354934 (84 worldwide citation)

Erythropoietin (EPO) can be delivered systemically in therapeutically or prophylactically effective amounts by pulmonary administration using a variety of pulmonary delivery devices, including nebulizers, metered dose inhalers and powder inhalers. Aerosol administration of EPO in accordance with thi ...


9
Murakami Kazuo, Ueno Naoto, Kato Yukio: Protein, dna and use thereof.. Takeda Chemical Industries, Scitech Research, March 13, 1991: EP0416578-A2 (78 worldwide citation)

Disclosed are (1) a Xenopus laevis bone morphogenetic protein (BMP), (2) a DNA comprising a DNA segment coding for a Xenopus laevis BMP, (3) a transformant bearing a DNA comprising a DNA segment coding for a Xenopus laevis BMP and (4) a method for preparing the Xenopus laevis BMP which comprises cul ...


10
Ross G Clark: Method for treatment or prevention of obesity. Genentech, Janet E Hasak, January 28, 1997: US05597797 (77 worldwide citation)

A method is disclosed for treating obese mammals or preventing obesity from occurring in mammals. This method involves administering to the mammal an effective amount of growth hormone in combination with an effective amount of IGF-I. Preferably, the growth hormone is given so as to have a maintaine ...